Create Account | Sign In: Author or Forum

 
News  |  Journals  |  Conferences  |  Opinion  |  Articles  |  Forums  |  Twitter    
 
Category: Endocrinology | Diabetes | Nursing | News

Back to Health News

Type 1 Diabetes May Develop More Slowly Than Thought

Last Updated: February 21, 2012.

 

Study finds gradual decline in insulin production, which could extend treatment options

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Study finds gradual decline in insulin production, which could extend treatment options.

TUESDAY, Feb. 21 (HealthDay News) -- Insulin production may continue for decades after the onset of type 1 diabetes, according to a new study.

The findings add to growing evidence that the period of time for treatment after the onset of the disease is longer than previously believed, the Massachusetts General Hospital researchers said.

"Traditionally, it was thought that beta cell function completely ceased in patients with advanced type 1 diabetes. However, data from this study and others suggest that the pancreas continues to function at some level even decades after the onset of type 1 diabetes," study leader Dr. Denise Faustman, director of the MGH Immunobiology Laboratory, said in a hospital news release.

Beta cells are a type of cell in the pancreas that produce and store insulin.

The researchers analyzed blood samples from 182 patients with type 1 diabetes and found that C-peptide production can continue for decades after disease onset and remains responsive to blood sugar levels. C-peptide is a marker of insulin secretion/beta cell function.

C-peptide levels were lower in patients who had type 1 diabetes for a longer time, but the decrease was gradual and not the sudden decline believed to occur in people with the disease.

Even among patients who'd had type 1 diabetes for 31 to 40 years, 10 percent still produced C-peptide and beta cell functioning remained intact at very low C-peptide levels, according to the study in the March issue of the journal Diabetes Care.

Researchers say the new findings suggest that type 1 diabetes patients with low C-peptide levels or advanced disease may benefit from new treatments to preserve or enhance beta cell function.

"Our results contribute to a growing body of evidence suggesting there might be a longer window for therapeutic intervention in this disease and also may help explain the transient restoration of insulin production we saw in patients who received BCG (the generic drug bacillus Calmette-Guerin) in our phase 1 clinical trial," Faustman said.

More information

Juvenile Diabetes Research Foundation International has more about type 1 diabetes.

SOURCE: Massachusetts General Hospital, news release, Feb. 21, 2012

Copyright © 2012 HealthDay. All rights reserved.


Previous: Medtronic Stent Approved to Treat Coronary Artery Disease Next: Study: No Significant Rise in Seizure Risk From Common Kids' Vaccine

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.